Chris Hand, CEO of Abingdon Health (A specialist medical diagnostics company), pictured here on the right at Birmingham Airport, has appeared in the University of Birmingham’s, “Birmingham Heroes: driving economic growth” campaign.
Bioscience Ventures (a former Abingdon Health Group company) is an innovative example of a successful collaboration between the university and business.
Located on the University of Birmingham campus, this joint-venture specialises in the commercialisation of medical diagnostics and services.
Bioscience Ventures manages two wholly owned subsidiaries. Alta Bioscience, a specialist biochemical reagent manufacturer and ISO 17025: 2005 accredited analytical services provider and Serascience, a specialist cancer diagnostics company which has just launched the first point-of-care test for myeloma (blood cancer), called Seralite®.
Pictured with Chris Hand is Professor Tim Dafforn from the University of Birmingham who is researching new techniques and pioneering the use of synthetic biology in Industry.
The creation of Bioscience Ventures between Abingdon Health and the University has helped Professor Dafforn progress development of several new diagnostic techniques.
Collaboration and the transfer of skills and knowledge between universities and industry is absolutely necessary for delivering benefits to society and the wider economy, something Abingdon Health and the University of Birmingham are highly engaged with. Comprising of dedicated medical diagnostics companies, Abingdon Health is driving collaboration across its group to provide exceptional poit-of-care diagnostics products and services in the healthcare sector.